Innate Pharma : ASCO 2018 : premiers résultats encourageants pour monalizumab en combinaison
>Activité encourageante de la combinaison monalizumab + durvalumab dans le cancer colorectal - Innate Pharma et son partenaire Astrazeneca ont présenté un poster, lors de l’ASCO, témoignant d’une activité anti-tumorale encourageante de la combinaison monalizumab (Innate) + durvalumab (IMFINZI, Astrazeneca) chez les patients atteints d’un cancer colorectal de type microsatellite-stable en rechute et/ou métastatique (MSS-CRC). Sur 40 patient évaluables de l’extension de...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.